These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 32929230)

  • 41. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C; Bollaerts K
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
    Dicembrini I; Montereggi C; Nreu B; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2020 Jan; 159():107981. PubMed ID: 31870827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dipeptidyl peptidase-4 inhibitor treatment could decrease
    Chen HH; Chen CC; Ho CW; Hsieh MC; Hsu SP; Lin CL; Kao CH
    Postgrad Med; 2020 Nov; 132(8):714-719. PubMed ID: 32633173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
    Mulvihill EE
    Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety.
    Matteucci E; Giampietro O
    Curr Med Chem; 2011; 18(31):4753-60. PubMed ID: 21919850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
    Frandsen CS; Madsbad S
    Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
    Abbatecola AM; Maggi S; Paolisso G
    Drugs Aging; 2008; 25(11):913-25. PubMed ID: 18947259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
    Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
    Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    Amori RE; Lau J; Pittas AG
    JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
    Kim SC; Glynn RJ; Liu J; Everett BM; Goldfine AB
    Acta Diabetol; 2014 Dec; 51(6):1015-23. PubMed ID: 25311055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Still a role for DPP-4 inhibitors in 2020?].
    Caironi V; Jornayvaz FR; Gariani K
    Rev Med Suisse; 2020 Jun; 16(697):1186-1190. PubMed ID: 32520456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence.
    Pala L; Rotella CM
    J Diabetes Res; 2013; 2013():590456. PubMed ID: 23853775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
    Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
    J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
    Charoenngam N; Rittiphairoj T; Ponvilawan B; Ungprasert P
    Diabetes Metab Syndr; 2021; 15(1):249-255. PubMed ID: 33465685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Incretin mimetic drugs: therapeutic positioning].
    López Simarro F
    Semergen; 2014 Jul; 40 Suppl 2():25-33. PubMed ID: 25311717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.
    Bouchi R; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Diabetes Metab Res Rev; 2018 Feb; 34(2):. PubMed ID: 29054111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Seong JM; Yee J; Gwak HS
    Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
    Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
    Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.